Area of Focus: Cell and Gene Therapies

MyoPax is developing regenerative therapies for muscle diseases with significant unmet need. A spin-out from Charité and the Helmholtz Association, and supported by top EU innovation programs, MyoPax combines a proprietary muscle stem cell platform with precise mRNA-based gene editing to treat genetic and acquired muscle weakness. The biotech is transitioning from preclinical to clinical stage. It operates in Berlin (Bayer Co.Lab) and Copenhagen (BII/Novo Nordisk Foundation).